Recombinant human activated protein C upregulates cyclooxygenase-2 expression in endothelial cells via binding to endothelial cell protein C receptor and activation of protease-activated receptor-1

Summary

Prostacyclin (PGI₂) has beneficial cytoprotective properties, is a potent inhibitor of platelet aggregation and has been reported to improve microcirculatory blood flow during sepsis. The formation of PGI₂ in response to proinflammatory cytokines is catalysed by the inducible cyclooxygenase (COX) isoform COX-2. Recombinant human activated protein C (rhAPC, drotrecogin alfa (activated)) was shown to have multiple biological activities in vitro and to promote resolution of organ dysfunction in septic patients. Whether rhAPC exerts its beneficial effects by modulating prostanoid generation is unknown up to now. It was therefore the aim of the study to examine the in vitro effect of rhAPC on COX-2-mRNA-expression and PGI₂ release from human umbilical vein endothelial cells (HUVEC). We found that rhAPC, at supra-therapeutical concentrations (500ng/ml-20μg/ ml), upregulated the amount of COX-2-mRNA in HUVEC at t=3–9h and caused a time- and dose-dependent release of 6-keto PGF_1α, the stable hydrolysis product of prostacyclin. RhAPC further increased the stimulating effect of tumor necrosis factor-α (TNF-α) and thrombin on COX-2-mRNA-levels. Transcript levels of cyclooxygenase-1 (COX-1) and prostagland-in I2 synthase, however, were unaffected by the stimulation with rhAPC or thrombin. The upregulatory effect on COX2-mRNA levels was specific for rhAPC since the zymogen protein C in equimolar concentrations had no effect on COX-2-mRNA-levels or 6keto PGF_1α-release. Western Blot analysis revealed an increase of COX-2-protein content in HUVEC after treatment with rhAPC. As shown by experiments using monoclonal antibodies against the thrombin receptor PAR-1 (mAb=ATAP2) and against the endothelial protein C receptor (EPCR; mAb=RCR-252), the effect of rhAPC on COX-2-mRNA up-regulation was mediated by binding to the EPCR-receptor and signaling via PAR-1. These results demonstrate that induction of COX-2-expression is an important response of HUVEC to stimulation with rhAPC and may represent a new molecular mechanism, by which rhAPC promotes upregulation of prostanoid production in human endothelium.

Keywords

Activated protein C - drotrecogin alfa (activated) - cyclooxygenase-2 - prostacyclin - endothelium

^* GH is an employee of Lilly Germany GmbH, Bad Homburg

• References

• 1 Esmon CT, Taylor FB, Snow RT. Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost 1991; 66: 1605
• 2 Joyce D, Grinnell BW. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factorκ B. Crit Care Med 2002; 30: S288-93.
• 3 Cheng T, Liu D, Griffin JH. et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003; 9: 338-42.
• 4 Zeng W, Matter WF, Yan SB. et al. Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling. Crit Care Med 2004; 32 (Suppl) S3028
• 5 Uchiba M, Okajima K, Ito Y, et al. Activated protein C induces endothelial cell proliferation by mitogen-activated protein kinase activation in vitro and angiogenesis in vivo. Circ Res 2004; 95: 34-41.
• 6 Fukudome J, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994; 269: 26486-91.
• 7 Riewald M, Petrovan RJ, Donner A. et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296: 1880-2.
• 8 Ruf W. Protease-activated receptor signaling in the regulation of inflammation. Crit Care Med 2004; 32 (Suppl.) S287-92.
• 9 Hoffmann JN, Vollmar B, Laschke MW. et al. Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia. Crit Care Med 2004; 32: 1011-7.
• 10 Schoots IG, Levi M, van Vliet AK. et al. Inhibition of coagulation and inflammation by activated protein C or antithrombin reduces intestinal ischemia/ reperfusion injury in rats. Crit Care Med 2004; 32: 1375-83.
• 11 Bernard GR, Vincent JL, Laterre PF. et al. for the PROWESS study group. Efficacy and safety of recombinant activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
• 12 Vincent JL, Angus DC, Artigas A. et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003; 31: 834-40.
• 13 Bernard GR, Margolis BD, Shanies HM. et al. Extended evaluation of recombinant human activated protein C united states trial (ENHANCE US) – a singlearm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest 2004; 125: 2206-16.
• 14 Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci 1992; 89: 7384-8.
• 15 Houliston RA, Keogh RJ, Sugden D. et al. Proteaseactivated receptors upregulate cyclooxygenase-2 expression in human endothelial cells. Thromb Haemost 2002; 88: 321-8.
• 16 Moncada S. Biological importance of prostacyclin. Br J Pharmacol 1982; 76: 3-31.
• 17 De Backer D, Creteur J, Preiser JC. et al. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 2002; 166: 98-104.
• 18 Möller AD, Grände PO. Beneficial effects of lowdose prostacyclin on cat intestinal perfusion during endotoxemia as evaluated with microdialysis and oxygen transport variables. Crit Care Med 2001; 29: 351-8.
• 19 Kiefer P, Tugtekin I, Wiedeck H. et al. Hepatosplanchnic metabolic effects of the stable prostacyclin analogue iloprost in patients with septic shock. Intensive Care Med 2001; 27: 1179-86.
• 20 Lehmann C, Taymoorian K, Wauer H. et al. Effects of the stable prostacyclin analogue iloprost on the plasma disappearance rate of indocyanine green in human septic shock. Intensive Care Med 2000; 26: 1557-60.
• 21 Oh-ishi S, Utsunomiya I, Yamamoto T. et al. Effects of prostanglandins and cyclic AMP on cytokine production in rat leukocytes. Eur J Pharmacol 1996; 300: 255-9.
• 22 Jones G, Hurley JV. The effect of prostacyclin on the adhesion of leucocytes to injured vascular endothelium. J Pathol 1984; 142: 51-9.
• 23 Jaffe EA, Nachman RL, Becker CG. et al. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-56.
• 24 Weber A, Nikolic N, Varandi K. et al. Analytical comparison of recombinant and plasma-derived activated protein C (APC). Ann Hematol 2003; 82 (Suppl 1) S90
• 25 Ye X, Fukudome K, Tsuneyoshi N. et al. The endothelial cell protein C receptor (EPCR) functions as a primary receptor for protein C activation on endothelial cells in arteries, veins, and capillaries. Biochem Biophys Res Com 1999; 259: 671-7.
• 26 Backer De. Is there a place for prostacyclin in the treatment of septic shock ? Intensive Care Med 2001; 27: 1110-1112
• 27 Caspary L, Creutzig A, Alexander K. Intravenous infusion of iloprost in arterial occlusive disease: Dosedependent effects on skin microcirculation. Eur J Clin Pharmacol 1991; 41: 131-6.
• 28 Bouskela E, Rubanyi GM. Effects of iloprost, a stable prostacyclin analog, and its combination with N w -nitro-L-arginine on early events following lipopolysaccharide injection: Observations in the hamster cheek pouch microcirculation. Int J Microcirc 1995; 15: 170-80.
• 29 Möller AD, Grände PO. Low-dose prostacyclin has potent capillary permeability reducing effects in cat skeletal muscle in vivo. Am J Physiol 1997; 273: H200-7.
• 30 Bihari DJ, Tinker J. The therapeutic value of vasodilator prostaglandins in multiple organ failure associated with sepsis. Intensive Care Med 1988; 15: 2-7.
• 31 Eichelbrönner O, Reinelt H, Wiedeck H. et al. Aerosolized prostacyclin and inhaled nitric oxide in septic shock – different effects on splanchnic oxygenation ?. Intensive Care Med 1996; 22: 880-7.
• 32 Taylor Jr FB, Stearns-Kurosawa DJ, Kurosawa S. et al. The endothelial protein C receptor aids in host defense against Escherichia coli sepsis. Blood 2000; 95: 1680-6.
• 33 Esmon CT. Structure and functions of the endothelial cell protein C receptor. Crit Care Med 2004; 32 (Suppl.) S298-S301.
• 34 Mosnier LO, Griffin JH. Inhibition of staurosporine- induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J 2003; 373: 65-70.
• 35 Joyce DE, Gelbert L, Ciaccia A. et al. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276: 11199-203.
• 36 Heyderman RS, Klein NJ, Shennan I G. et al. Deficiency of prostaglandin production in meningcoccal shock. Arch Dis Child 1991; 66: 1296-9.
• 37 Grey ST, Tsuchida A, Hau H. et al. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J Immunol 1994; 153: 3664-72.
• 38 Yuksel M, Okajima K, Uchiba M. et al. Activated protein C inhibits lipopolysaccharide-induced tumornecrosis factor- α production by inhibiting activation of both nuclear factor- κ B and activator protein-1 in human monocytes. Thromb Haemost 2002; 88: 267-73.
• 39 Dhainaut JF, Yan SB, Margolis BD. et al. for the PROWESS Sepsis Study Group. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 2003; 90: 642-53.
• 40 Macias WL, Dhainaut JF, Yan SC. et al. Pharmacokinetic- pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clin Pharmacol Ther 2002; 72: 391-402.